Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gareth T Jones

Showing results (131-140 of 147) with videos related to

Pageof 15
Sort By:
Annals of the Rheumatic Diseases|June 4, 2021
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaborationUlf Lindström, Daniela Di Giuseppe, Bénédicte Delcoigne, et al.
Seminars in Arthritis and Rheumatism|August 19, 2022
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaborationLykke M Ørnbjerg, Louise Linde, Stylianos Georgiadis, et al.
Seminars in Arthritis and Rheumatism|December 4, 2022
Corrigendum to 'Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration' [Seminars in Arthritis and Rheumatism 56 (2022) 1-13/152081]Lykke M Ørnbjerg, Louise Linde, Stylianos Georgiadis, et al.
Rheumatology (Oxford, England)|January 22, 2020
Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritisBrigitte Michelsen, Lykke Midtbøll Ørnbjerg, Tore K Kvien, et al.
Investigative Ophthalmology & Visual Science|June 4, 2020
Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility LociXiu-Feng Huang, Zhixiu Li, Erika De Guzman, et al.
Joint Bone Spine|November 28, 2024
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritisMarion Pons, Stylianos Georgiadis, Mikkel Østergaard, et al.
Seminars in Arthritis and Rheumatism|February 1, 2024
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practiceSara Nysom Christiansen, Simon Horskjær Rasmussen, Marion Pons, et al.
The Journal of Rheumatology|December 1, 2022
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor TreatmentLykke Midtbøll Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis, et al.
Arthritis Care & Research|January 18, 2021
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European CountriesBrigitte Michelsen, Stylianos Georgiadis, Daniela Di Giuseppe, et al.
Arthritis Research & Therapy|January 31, 2025
Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registriesAdrian Ciurea, Seraphina Kissling, Andrea Götschi, et al.
Pageof 15

Showing results (131-140 of 147) with videos related to

Sort By:
Pageof 15
Annals of the Rheumatic Diseases|June 4, 2021
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaborationUlf Lindström, Daniela Di Giuseppe, Bénédicte Delcoigne, et al.
Seminars in Arthritis and Rheumatism|August 19, 2022
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaborationLykke M Ørnbjerg, Louise Linde, Stylianos Georgiadis, et al.
Seminars in Arthritis and Rheumatism|December 4, 2022
Corrigendum to 'Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration' [Seminars in Arthritis and Rheumatism 56 (2022) 1-13/152081]Lykke M Ørnbjerg, Louise Linde, Stylianos Georgiadis, et al.
Rheumatology (Oxford, England)|January 22, 2020
Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritisBrigitte Michelsen, Lykke Midtbøll Ørnbjerg, Tore K Kvien, et al.
Investigative Ophthalmology & Visual Science|June 4, 2020
Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility LociXiu-Feng Huang, Zhixiu Li, Erika De Guzman, et al.
Joint Bone Spine|November 28, 2024
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritisMarion Pons, Stylianos Georgiadis, Mikkel Østergaard, et al.
Seminars in Arthritis and Rheumatism|February 1, 2024
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practiceSara Nysom Christiansen, Simon Horskjær Rasmussen, Marion Pons, et al.
The Journal of Rheumatology|December 1, 2022
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor TreatmentLykke Midtbøll Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis, et al.
Arthritis Care & Research|January 18, 2021
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European CountriesBrigitte Michelsen, Stylianos Georgiadis, Daniela Di Giuseppe, et al.
Arthritis Research & Therapy|January 31, 2025
Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registriesAdrian Ciurea, Seraphina Kissling, Andrea Götschi, et al.
Pageof 15